DNA Link Inc (127120) - Total Liabilities

Latest as of March 2026: ₩53.95 Billion KRW ≈ $36.56 Million USD

Based on the latest financial reports, DNA Link Inc (127120) has total liabilities worth ₩53.95 Billion KRW (≈ $36.56 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore DNA Link Inc annual equity growth to track the company's year-over-year net asset growth rate.

DNA Link Inc - Total Liabilities Trend (2011–2025)

This chart illustrates how DNA Link Inc's total liabilities have evolved over time, based on quarterly financial data. See DNA Link Inc free cash flow efficiency to measure how efficiently the company converts operating cash flow to free cash.

DNA Link Inc Competitors by Total Liabilities

The table below lists competitors of DNA Link Inc ranked by their total liabilities.

Company Country Total Liabilities
Sun International Ltd
JSE:SUI
South Africa ZAC9.98 Billion
Hi target Navigation Tech Co
SHE:300177
China CN¥1.42 Billion
Anhui Huilong Agricultural Means of Production Co Ltd
SHE:002556
China CN¥7.74 Billion
Senvest Capital Inc.
TO:SEC
Canada CA$3.96 Billion
Kvutzat Acro Ltd.
TA:ACRO
Israel ILA4.96 Billion
Mitek Systems Inc
NASDAQ:MITK
USA $117.47 Million
MD Pictures Tbk PT
JK:FILM
Indonesia Rp566.76 Billion
Energy Absolute Public Company Limited
BK:EA
Thailand ฿55.05 Billion

Liability Composition Analysis (2011–2025)

This chart breaks down DNA Link Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market value of DNA Link Inc.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 1.72 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.60 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.38 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how DNA Link Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for DNA Link Inc (2011–2025)

The table below shows the annual total liabilities of DNA Link Inc from 2011 to 2025.

Year Total Liabilities Change
2025-12-31 ₩54.44 Billion
≈ $36.90 Million
+85.46%
2024-12-31 ₩29.36 Billion
≈ $19.89 Million
+135.23%
2023-12-31 ₩12.48 Billion
≈ $8.46 Million
-20.09%
2022-12-31 ₩15.62 Billion
≈ $10.58 Million
+89.40%
2021-12-31 ₩8.25 Billion
≈ $5.59 Million
-40.42%
2020-12-31 ₩13.84 Billion
≈ $9.38 Million
-14.77%
2019-12-31 ₩16.24 Billion
≈ $11.00 Million
+5.02%
2018-12-31 ₩15.46 Billion
≈ $10.48 Million
+996.65%
2017-12-31 ₩1.41 Billion
≈ $955.48K
-94.14%
2016-12-31 ₩24.04 Billion
≈ $16.29 Million
+11.69%
2015-12-31 ₩21.53 Billion
≈ $14.59 Million
+68.92%
2014-12-31 ₩12.74 Billion
≈ $8.64 Million
+3.34%
2012-12-31 ₩12.33 Billion
≈ $8.36 Million
+37.43%
2011-12-31 ₩8.97 Billion
≈ $6.08 Million
--

About DNA Link Inc

KQ:127120 Korea Biotechnology
Market Cap
$676.82 Million
₩998.73 Billion KRW
Market Cap Rank
#10548 Global
#267 in Korea
Share Price
₩28950.00
Change (1 day)
+4.32%
52-Week Range
₩15180.00 - ₩48900.00
All Time High
₩48900.00
About

JS Link, Inc., a genome-based biotechnology company, focuses on the research and development of genome analysis services in South Korea and internationally. Its next generation sequencing services include whole genome sequencing, De Novo sequencing, whole exome/targeted sequencing, transcriptome sequencing, epigenome sequencing, and single-cell RNA sequencing. The company also provides microarray… Read more